 | • レポートコード：MRC-IM30002 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、147ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2021年に672億ドルであった世界の神経変性疾患治療市場規模が、2022年から2027年の間にCAGR 5.4％で成長し、2027年までに924億ドルに達すると予測しています。本調査レポートでは、神経変性疾患治療の世界市場について総合的に調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、疾患別（多発性硬化症、パーキンソン病、アルツハイマー病、脊髄性筋萎縮症（SMA）、ハンチントン病分析、薬剤種類別（N-メチル-D-アスパラギン酸受容体拮抗薬、選択的セロトニン再取り込み阻害剤、ドーパミン阻害剤、その他）分析、投与経路別（経口薬、注射薬、その他）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目をまとめています。なお、本書に掲載されている企業情報には、Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. UCB S.A.などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の神経変性疾患治療市場規模：疾患別 - 多発性硬化症における市場規模 - パーキンソン病における市場規模 - アルツハイマー病における市場規模 - 脊髄性筋萎縮症（SMA）における市場規模 - ハンチントン病における市場規模 ・世界の神経変性疾患治療市場規模：薬剤種類別 - N-メチル-D-アスパラギン酸受容体拮抗薬の市場規模 - 選択的セロトニン再取り込み阻害剤の市場規模 - ドーパミン阻害剤の市場規模 - その他薬剤の市場規模 ・世界の神経変性疾患治療市場規模：投与経路別 - 経口薬の市場規模 - 注射薬の市場規模 - その他投与経路の市場規模 ・世界の神経変性疾患治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他流通チャネルの市場規模 ・世界の神経変性疾患治療市場規模：地域別 - 北米の神経変性疾患治療市場規模 - アジアの神経変性疾患治療市場規模 - 欧州の神経変性疾患治療市場規模 - 中南米の神経変性疾患治療市場規模 - 中東・アフリカの神経変性疾患治療市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global neurodegenerative disease treatment market size reached US$ 67.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 92.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients’ life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurodegenerative disease treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on indication, drug type, route of administration and distribution channel.
Breakup by Indication:
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy (SMA)
Huntington’s Disease
Others
Breakup by Drug Type:
N-methyl-D-aspartate Receptor Antagonists
Selective Serotonin Reuptake Inhibitors
Dopamine Inhibitors
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report:
How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global neurodegenerative disease treatment market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Neurodegenerative Disease Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Indication
6.1 Multiple Sclerosis
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Parkinson’s Disease
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Alzheimer’s Disease
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Spinal Muscular Atrophy (SMA)
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Huntington’s Disease
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Drug Type
7.1 N-methyl-D-aspartate Receptor Antagonists
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Selective Serotonin Reuptake Inhibitors
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Dopamine Inhibitors
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Biogen
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Boehringer Ingelheim International GmbH
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 F. Hoffmann-La Roche AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.4 GlaxoSmithKline Plc
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 Merck & Co. Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Novartis AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Pfizer Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Sanofi S.A
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Teva Pharmaceutical Industries Ltd.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 UCB S.A
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
Figure 2: Global: Neurodegenerative Disease Treatment Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Neurodegenerative Disease Treatment Market: Breakup by Indication (in %), 2021
Figure 5: Global: Neurodegenerative Disease Treatment Market: Breakup by Drug Type (in %), 2021
Figure 6: Global: Neurodegenerative Disease Treatment Market: Breakup by Route of Administration (in %), 2021
Figure 7: Global: Neurodegenerative Disease Treatment Market: Breakup by Distribution Channel (in %), 2021
Figure 8: Global: Neurodegenerative Disease Treatment Market: Breakup by Region (in %), 2021
Figure 9: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Neurodegenerative Disease Treatment (Parkinson’s Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Neurodegenerative Disease Treatment (Parkinson’s Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Neurodegenerative Disease Treatment (Alzheimer’s Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Neurodegenerative Disease Treatment (Alzheimer’s Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Neurodegenerative Disease Treatment (Huntington’s Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Neurodegenerative Disease Treatment (Huntington’s Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Neurodegenerative Disease Treatment (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Neurodegenerative Disease Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Neurodegenerative Disease Treatment (Injectable) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Neurodegenerative Disease Treatment (Injectable) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: North America: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: North America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: United States: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: United States: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Canada: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Canada: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Asia-Pacific: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Asia-Pacific: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: China: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: China: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Japan: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Japan: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: India: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: India: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: South Korea: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: South Korea: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Australia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Australia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Indonesia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Indonesia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Europe: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Europe: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Germany: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Germany: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: France: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: France: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: United Kingdom: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: United Kingdom: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Italy: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Italy: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Spain: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Spain: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Russia: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Russia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Latin America: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Latin America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Brazil: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Brazil: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Mexico: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Mexico: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Middle East and Africa: Neurodegenerative Disease Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Middle East and Africa: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Middle East and Africa: Neurodegenerative Disease Treatment Market: Breakup by Country (in %), 2021
Figure 90: Global: Neurodegenerative Disease Treatment Industry: SWOT Analysis
Figure 91: Global: Neurodegenerative Disease Treatment Industry: Value Chain Analysis
Figure 92: Global: Neurodegenerative Disease Treatment Industry: Porter's Five Forces Analysis
